Both in Pharmaceuticals
Rigel Pharmaceuticals Inc. (New) vs Jade Biosciences
Over the past year RIGL returned +70.1% and JBIO returned +64.5%; their daily moves had a correlation of 0.30.
RIGL +70.1% JBIO +64.5%Growth of $1, one year, split-adjusted
| Metric | RIGL | JBIO |
|---|---|---|
| Price | $48.89 | $14.18 |
| Market cap | $913.3M | $901.8M |
| Today | −0.95% | −1.18% |
| 1 month | +5.2% | −32.0% |
| 6 months | +90.1% | +6.9% |
| Year to date | +14.1% | −8.1% |
| 1 year | +70.8% | +67.2% |
| Revenue growth (YoY) | −22.6% | — |
| Gross margin | 89.2% | — |
| Net margin | 22.0% | — |
| P/E (TTM) | 2.8× | — |
| Price / sales | 3.3× | — |
| Net cash | $56.1M | $461.2M |
| Dividend yield | — | — |
| Volatility (60d) | 40.5% | 58.9% |
| Short % of float | 19.3% | 26.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).